20 July 2023 
EMA/CHMP/291588/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Spikevax 
COVID-19 mRNA vaccine (nucleoside-modified) 
On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Spikevax. 
The marketing authorisation holder for this medicinal product is Moderna Biotech Spain, S.L. 
The CHMP adopted two extensions to the existing indication, to extend the use of the vaccine from 6 
years of age and older to children from 6 months of age and older and to extend the use of the vaccine to 
individuals regardless of their vaccination status. For information, the full indication for Spikevax bivalent 
Original/Omicron BA.4-5 is as follows:2 
Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunisation to prevent 
COVID-19 caused by SARS-CoV-2 in individuals 6 years months of age and older who have 
previously received at least a primary vaccination course against COVID-19 (see sections 4.2 and 
5.1). 
The use of this vaccine should be in accordance with official recommendations. 
For information, the indications for other compositions of the vaccine are provided in the summary of 
product characteristics (SmPC) for Spikevax. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.  
 
 
 
 
 
 
 
 
 
